82 results
Page 3 of 5
8-K
EX-10.1
21gjpqg9rq p5hn
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
59ykp5
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
424B5
lold4ab
15 Sep 21
Prospectus supplement for primary offering
9:47pm
8-K
EX-99.1
v1wfae7clu ymfd
23 Aug 21
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
4:23pm
8-K
EX-99.1
ysxo99 gf1yz
5 Aug 21
Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
4:08pm
8-K
EX-99.1
ycw21eqbo7t8fb
9 Jul 21
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
4:02pm
8-K
EX-99.1
gn39coonh v5f
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
EX-99.1
tlf6fmhm
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
EX-99.1
0xoqu54mo 538fw
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
8-K
lmuxwv
14 Oct 20
Entry into a Material Definitive Agreement
6:04am
424B5
4c3ijl5t9cbto
13 Oct 20
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
c6995qj3
15 Sep 20
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
12:00am